Abstract
Immunotherapy, particularly immune checkpoint inhibitors (ICIs), has revolutionized cancer treatment by harnessing the host immune system to target malignancies. Melanoma, head and neck squamous cell carcinoma (HNSCC), and triple-negative breast cancer (TNBC) were among the first solid tumors to gain regulatory approval for ICIs due to their immunogenicity and unmet clinical needs. Melanoma exemplifies the success of ICI therapy, with durable responses driven by its high mutation burden and neoantigen landscape, yet both primary and acquired resistance remain major challenges. In contrast, HNSCC demonstrates clinically meaningful but modest responses in the context of a highly immunosuppressive tumor microenvironment, while TNBC derives limited benefit from ICI, often requiring combination strategies to achieve efficacy. Resistance to ICIs arises from complex tumor-intrinsic, microenvironmental, and systemic mechanisms that collectively undermine effective anti-tumor immunity. This review highlights both shared and cancer-specific mechanisms of ICI resistance across melanoma, TNBC and HNSCC. We also discuss emerging strategies, including combination therapies, neoantigen-based vaccines, adoptive T cell therapies, and precision oncology approaches, to overcome resistance and improve clinical outcomes. Together, these insights provide a framework for optimizing immunotherapy and advance durable benefit in these challenging malignancies.
Keywords
Immune checkpoint inhibitors, Immunotherapy resistance, Melanoma, Head and neck squamous cell carcinoma, Triple-negative breast cancer, Tumor microenvironment, Tumor mutation burden, Neoantigens, Oncogenic pathways, Antigen presentation